NeuroSense Says Phase 2b ALS Study Meets Primary Endpoint

NeuroSense Therapeutics said its Phase 2b PARADIGM study of PrimeC in ALS met the primary efficacy endpoint, showing a statistically significant reduction in TDP-43 levels versus placebo. The result is a meaningful clinical development for the company and supports the drug's mechanism in a high-need indication. The news is likely positive for NRSN shares, though it is still early-stage and not yet a pivotal or regulatory milestone.

Analysis

NeuroSense Therapeutics said its Phase 2b PARADIGM study of PrimeC in ALS met the primary efficacy endpoint, showing a statistically significant reduction in TDP-43 levels versus placebo. The result is a meaningful clinical development for the company and supports the drug's mechanism in a high-need indication. The news is likely positive for NRSN shares, though it is still early-stage and not yet a pivotal or regulatory milestone.